After the FDA said last year it would keep a closer eye on the potential complications of a type of permanent heart plug designed to cut the risk of stroke, Boston Scientific has put forward ...
Please provide your email address to receive an email when new articles are posted on . In a head-to-head trial of the Amplatzer Amulet and Watchman FLX left atrial appendage closure devices, the ...
SWISS-APERO is the first randomized clinical trial comparing Amulet with the new generation Watchman FLX device in terms of residual left atrial appendage (LAA) patency after percutaneous LAA closure ...
MARLBOROUGH, Mass., July 21, 2021 /PRNewswire/ -- Today, Boston Scientific (NYSE: BSX) announced positive 24-month results from the PINNACLE FLX clinical trial assessing the safety and efficacy of the ...
In the showdown between left atrial appendage (LAA) closure devices, the Amplatzer Amulet outperformed Watchman for peridevice leaks (PDL) in one trial longer term but not in another. At 12 months of ...
The Cottage Heart & Vascular Center’s structural heart team at Santa Barbara Cottage Hospital (SBCH) recently performed their 1,000th WATCHMAN device procedure, a minimally invasive solution for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results